MedGenome, a global leader in genomics-driven diagnostics and research, has acquired a majority investment in Green Cross Genetics Lab, a Gujarat-based pathology chain with over 30 years of operations. This move combines Green Cross's established network of 17 laboratories and 35 collection centers with MedGenome's advanced multiomics capabilities. The partnership aims to expand access to affordable genetic testing across India's Tier 2 and Tier 3 cities.
Green Cross's Proven Foundation Meets Genomics Expertise
Founded by industry veteran Vinod Patel, Green Cross Genetics Lab has built a reputation for reliable pathology services over three decades. Senior pathologists and medical professionals with more than 30 years of clinical experience guide its operations. The company now employs over 500 staff and offers more than 800 diagnostic solutions, all under expert supervision to ensure precision and patient trust.
MedGenome brings South Asia's largest CAP-accredited end-to-end multiomics laboratory to the table. Its in-house AI and machine learning pipelines analyze genetic data, providing clinicians with actionable insights for complex diseases. This union addresses a key gap in Indian healthcare: integrating routine pathology with advanced genomics for earlier disease detection.
Strategic Expansion in Underserved Markets
Dr. Vedam Ramprasad, CEO of MedGenome, emphasized the partnership's role in strengthening presence in Gujarat and beyond. It supports MedGenome's mission to deliver affordable omics solutions where demand outpaces supply, particularly in smaller cities. Green Cross's infrastructure and distribution network will accelerate this rollout, making genetic insights more reachable for routine clinical use.
Vinod Patel, Promoter and Director of Green Cross, highlighted the synergy in infrastructure, technology, and expertise. The promoters commit to ongoing leadership, ensuring continuity amid growth. Together, the firms plan to integrate genomics into everyday diagnostics, offering clinicians comprehensive guidance for treatment decisions.
Implications for India's Diagnostics Landscape
Genomics testing has transformed disease management by identifying genetic risks before symptoms appear, yet high costs and limited access hinder adoption in India. This investment bridges that divide, potentially improving outcomes for conditions like cancer and rare disorders through data-driven precision medicine. As Indian firms scale such technologies, they position the country as a contender in global genomics innovation.
The collaboration promises broader national reach, combining local trust with cutting-edge tools. Patients stand to gain from faster, more accurate diagnoses, while clinicians benefit from enhanced decision-making support. Such partnerships signal a maturing diagnostics sector focused on equity and efficiency.
